Outline

LeadArtis´s proprietary Trimerbody® technology can be adapted to numerous protein configurations. One such key configuration includes monoclonal antibody (mAb) formatting which provides advantages over conventional mAbs including extensive and multiple simultaneous targeting, reduced size which could entail higher tissue penetrance, higher avidity/affinity for targets and a variety of effector possibilities such as immune system modulation, receptor agonism/antagonism, soluble factor neutralization and payload delivery.

LeadArtis news image

Schematic representation of a monospecific scFv-based N- terminal trimerbody (A), and a bispecific N-/C- terminal trimerbody (B)

LeadArtis news image

Functional characterization of purified trimerbodies. Reducing SDS-PAGE of purified N- trimebody (L36N) and N/C- trimerbody (L36N/COKT3) (A), antigen titration ELISA against plastic immobilized LK-111 (B) and FACS on CD3+ Jurkat cells (C).

LeadArtis news image

Serum stability of purified trimerbodies. ELISA against plastic immobilized LM-111 was performed after incubation 37ºC for different time periods in human serum.

Latest News

Leadartis successfully accomplishes the TERET project
07-04-2017

Leadartis is proud to announce the successful conclusion of the TERET (New Treatments for...

LeadArtis participates in the third Immunostimulatory Agonist Antibodies for Cancer Therapy (IACT) meeting
09-12-2016

The third IACT review meeting took place on October 25-26, 2016 in Frankfurt, Germany. LeadArtis...

Leadartis to present at BioSpain 2016 in Bilbao
25-08-2016

Leadartis will participate in BioSpain 2016 to be held...